Monte Rosa Therapeutics (GLUE) Operating Margin (2024 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Operating Margin of 1163.58% for Q1 2026, down 121543.0% year-over-year from N/an in Q1 2025, and up 34.91% quarter-over-quarter from 1787.67% in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Operating Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Operating Margin history runs 3 years deep, the most recent figure standing at 1163.58% for Q1 2026.
- In Q1 2026, Operating Margin fell 121543.0% year-over-year to 1163.58%; the TTM figure through Mar 2026 stood at 3448.33% (down 344699.0% YoY), while the FY2025 annual figure was 43.83%, up 6343.0% from the prior year.
- Operating Margin for Q1 2026 stood at 1163.58%, up from 1787.67% in the prior quarter.
- The five-year high for Operating Margin was 51.85% in Q1 2025, with the low at 3284.49% in Q1 2024.
- The 3-year median for Operating Margin is 287.84% (2024), against an average of 797.62%.
- Peak annual rise in Operating Margin reached 333634 bps in 2025, while the deepest fall reached 180911 bps in 2025.
- Monte Rosa Therapeutics' Operating Margin stood at 21.44% in 2024, then tumbled by 8437 bps to 1787.67% in 2025, then jumped by 35 bps to 1163.58% in 2026.
- Business Quant data shows GLUE's Operating Margin at 1163.58% in Q1 2026, 1787.67% in Q4 2025, and 21.98% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -547.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -547.84% |
| Mar 31, 2026 | -1,188.46% |
| Dec 31, 2025 | -1,787.67% |
| Sep 30, 2025 | -258.26% |
| Jun 30, 2025 | -11.09% |
| Mar 31, 2025 | 51.85% |
| Dec 31, 2024 | 21.44% |
| Sep 30, 2024 | -287.84% |
| Jun 30, 2024 | -695.25% |
| Mar 31, 2024 | -3,284.49% |